135 related articles for article (PubMed ID: 2481546)
21. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
22. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
Pollmann H
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
[TBL] [Abstract][Full Text] [Related]
23. Laboratory strategic defense initiatives against transmission of human immune deficiency virus in blood and blood products.
Ahmed SG
Niger Postgrad Med J; 2003 Dec; 10(4):254-9. PubMed ID: 15045022
[TBL] [Abstract][Full Text] [Related]
24. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
25. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
26. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation.
Trannoy LL; Terpstra FG; de Korte D; Lagerberg JW; Verhoeven AJ; Brand A; van Engelenburg FA
Vox Sang; 2006 Aug; 91(2):111-8. PubMed ID: 16907871
[TBL] [Abstract][Full Text] [Related]
27. [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems].
Burnouf T; Goubran HA; Radosevich M; El-Ekiaby M
Transfus Clin Biol; 2008 Jun; 15(3):129-34. PubMed ID: 18538608
[TBL] [Abstract][Full Text] [Related]
28. [Inactivation of viruses in Factor XIII concentrate by pasteurization].
Mauler R; Hilfenhaus J
Arzneimittelforschung; 1984; 34(11):1524-7. PubMed ID: 6543127
[TBL] [Abstract][Full Text] [Related]
29. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
30. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
[TBL] [Abstract][Full Text] [Related]
31. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
32. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
[TBL] [Abstract][Full Text] [Related]
34. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
[TBL] [Abstract][Full Text] [Related]
35. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
Buchacher A; Iberer G
Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
[TBL] [Abstract][Full Text] [Related]
36. [Properties and virus safety of a pasteurized antithrombin III concentrate].
Karges HE; Fuhge P; Heimburger N
Arzneimittelforschung; 1987 Jul; 37(7):756-8. PubMed ID: 2823838
[TBL] [Abstract][Full Text] [Related]
37. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
38. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
Welch J; Bienek C; Gomperts E; Simmonds P
Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
[TBL] [Abstract][Full Text] [Related]
39. [Virus inactivation in plasma fractions for therapeutic use].
Burnouf T; Martinache L; Goudemand M
Nouv Rev Fr Hematol (1978); 1987; 29(1):93-6. PubMed ID: 3588282
[TBL] [Abstract][Full Text] [Related]
40. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
Hilfenhaus J; Gröner A; Nowak T; Weimer T
Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
